Literature DB >> 22414880

Genetics of patent ductus arteriosus susceptibility and treatment.

Hanine Hajj1, John M Dagle.   

Abstract

The ductus arteriosus is a vital fetal structure designed to close shortly after birth. Although many physiologic and pharmacologic investigations have characterized the closure of this structure, genetic studies of persistent patency of the ductus arteriosus (patent ductus arteriosus, PDA) are relatively recent. Progress in the identification of specific genes associated with PDA is well behind that of many adult-onset diseases because of several reasons ranging from the lack of large biorepositories for this unique population to the belief that any genetic contribution to PDA is minimal. Viewing the PDA as a complex, developmentally influenced disease with both genetic and environmental risk factors has resulted in initial successes in some genetic studies. We will introduce several genetic approaches, which have been or are currently being applied to the study of PDA, that have been successful in identifying polymorphisms associated with adult diseases. Genetic investigations of PDA will be discussed with respect to heritability, in general, and to specific risk genes. Several animal models that have been used to study PDA-related genes will also be presented. Further advances in discovering genetic variation causing PDA will drive the more rational use of current therapies, and may help identify currently unknown targets for future therapeutic manipulation. Copyright Â
© 2012 Elsevier Inc. All rights reserved.

Mesh:

Substances:

Year:  2012        PMID: 22414880     DOI: 10.1053/j.semperi.2011.09.019

Source DB:  PubMed          Journal:  Semin Perinatol        ISSN: 0146-0005            Impact factor:   3.300


  14 in total

Review 1.  Novel drug targets for ductus arteriosus manipulation: Looking beyond prostaglandins.

Authors:  Elaine L Shelton; Gautam K Singh; Colin G Nichols
Journal:  Semin Perinatol       Date:  2018-05-10       Impact factor: 3.300

2.  CYP2C9*2 is associated with indomethacin treatment failure for patent ductus arteriosus.

Authors:  Sydney R Rooney; Elaine L Shelton; Ida Aka; Christian M Shaffer; Ronald I Clyman; John M Dagle; Kelli Ryckman; Tamorah R Lewis; Jeff Reese; Sara L Van Driest; Prince J Kannankeril
Journal:  Pharmacogenomics       Date:  2019-08       Impact factor: 2.533

Review 3.  Genetics of the patent ductus arteriosus (PDA) and pharmacogenetics of PDA treatment.

Authors:  Tamorah R Lewis; Elaine L Shelton; Sara L Van Driest; Prince J Kannankeril; Jeff Reese
Journal:  Semin Fetal Neonatal Med       Date:  2018-02-24       Impact factor: 3.926

4.  Polymorphisms in CYP2C9 are associated with response to indomethacin among neonates with patent ductus arteriosus.

Authors:  Caitlin J Smith; Kelli K Ryckman; Timothy M Bahr; John M Dagle
Journal:  Pediatr Res       Date:  2017-07-05       Impact factor: 3.756

5.  Identification of differentially regulated genes in human patent ductus arteriosus.

Authors:  Pratik Parikh; Haiqing Bai; Michael F Swartz; George M Alfieris; David A Dean
Journal:  Exp Biol Med (Maywood)       Date:  2016-07-28

6.  BMP9 and BMP10 are necessary for proper closure of the ductus arteriosus.

Authors:  Sandrine Levet; Marie Ouarné; Delphine Ciais; Charles Coutton; Mariela Subileau; Christine Mallet; Nicolas Ricard; Marie Bidart; Thierry Debillon; Francesca Faravelli; Caroline Rooryck; Jean-Jacques Feige; Emmanuelle Tillet; Sabine Bailly
Journal:  Proc Natl Acad Sci U S A       Date:  2015-06-08       Impact factor: 11.205

7.  Effects of Advancing Gestation and Non-Caucasian Race on Ductus Arteriosus Gene Expression.

Authors:  Nahid Waleh; Anne Marie Barrette; John M Dagle; Allison Momany; Chengshi Jin; Nancy K Hills; Elaine L Shelton; Jeff Reese; Ronald I Clyman
Journal:  J Pediatr       Date:  2015-08-08       Impact factor: 4.406

Review 8.  Clinical pharmacology of indomethacin in preterm infants: implications in patent ductus arteriosus closure.

Authors:  Gian Maria Pacifici
Journal:  Paediatr Drugs       Date:  2013-10       Impact factor: 3.022

9.  MATR3 disruption in human and mouse associated with bicuspid aortic valve, aortic coarctation and patent ductus arteriosus.

Authors:  Fabiola Quintero-Rivera; Qiongchao J Xi; Kim M Keppler-Noreuil; Ji Hyun Lee; Anne W Higgins; Raymond M Anchan; Amy E Roberts; Ihn Sik Seong; Xueping Fan; Kasper Lage; Lily Y Lu; Joanna Tao; Xuchen Hu; Ronald Berezney; Bruce D Gelb; Anna Kamp; Ivan P Moskowitz; Ronald V Lacro; Weining Lu; Cynthia C Morton; James F Gusella; Richard L Maas
Journal:  Hum Mol Genet       Date:  2015-01-07       Impact factor: 6.150

10.  Proteomics analysis of plasma protein changes in patent ductus arteriosus patients.

Authors:  Cheng Xu; Xiaoqi Su; Yong Chen; Yang Xu; Zhiqi Wang; Xuming Mo
Journal:  Ital J Pediatr       Date:  2020-05-19       Impact factor: 2.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.